The chief executive of asthma monitoring startup Respiri, Marjan Mikel, is also hoping to crack the US market. Reflecting on Pfizer’s bid for ResApp, Mikel said his company has had conversations with major pharmaceutical players but has yet to see a compelling offer for collaboration or a takeover.
Pfizer bid gives lung health start-ups some air time (smh.com.au)
